|
|
|
|
biological studies on Multiple Myeloma
The results from these in vitro experiments
on multiple myeloma cell lines and anti-angiogenesis assays and from
earlier animal studies on Atiprimod’s anti-osteoclastic
activity taken together form the basis for evaluating Atiprimod in multiple
myeloma and bone destruction due to cancer. Comparison of the various effects
elicited by Atiprimod with those associated with disease activity and disease
stage of multiple myeloma indicate that this drug has a unique therapeutic
potential as a treatment for this disease, as it simultaneously lowers serum
IL-6 and VEGF, two growth factors generally recognized to play the major
role in the pathophysiology of multiple myeloma, in addition to lowering
TNF-a, sIL-2r and IL-1 levels, three other growth factors associated with
the disease. An additional characteristic of Atiprimod that argues strongly
for its potential role in treating multiple myeloma is the effect it has
on inhibiting activated-osteoclast driven bone resorption, a key debilitating
factor associated with the pathology of multiple myeloma. This last characteristic may
be important to its potential use in treating other osteolytic bone diseases
such as metastatic breast and prostrate cancer.
|
|
|
technology Links
|
|